Home Featured Page 235

Featured

Latest

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

PT256 – Matthew D. Segall, Ph.D. – Consciousness, Capitalism, and Philosophy

PTSF70 – Depth Psychology, The Reach of the DEA, and Progress...

Psychedelics, Religion, and the DEA’s Quest for Soul

PT255 – Jasmine Virdi – Conservation, Covid, and Neurodivergence

Psychedelic Medicine Virtual Symposium – 8/28, 9/11, 9/25

PTSF72 – Breaking Down SB-519, with MAPS’ Ismail L. Ali

Optimi Health Joins First Psychedelic Exchange Traded Fund

Ian Burnstein Joins Wesana Health Advisory Board

Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol...

Active vs. Passive Coping Distinguishes Antidepressants and Psychedelics

1...234235236...304 Page 235 of 304

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

PT256 – Matthew D. Segall, Ph.D. – Consciousness, Capitalism, and Philosophy

PTSF70 – Depth Psychology, The Reach of the DEA, and Progress...

Psychedelics, Religion, and the DEA’s Quest for Soul

PT255 – Jasmine Virdi – Conservation, Covid, and Neurodivergence

Psychedelic Medicine Virtual Symposium – 8/28, 9/11, 9/25

PTSF72 – Breaking Down SB-519, with MAPS’ Ismail L. Ali

Optimi Health Joins First Psychedelic Exchange Traded Fund

Ian Burnstein Joins Wesana Health Advisory Board

Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol...

Active vs. Passive Coping Distinguishes Antidepressants and Psychedelics

EDITOR PICKS

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY